Table 3 Logistic regression analysis evaluating SCFAs in patients with MASLD grouped according to histological severity

Acetate

1.08

(0.59–1.96)

0.80

0.74

(0.4–1.38)

0.35

0.87

(0.38–1.99)

0.74

0.86

(0.44–1.68)

0.65

Propionate

2.23

(1.13–4.43)

0.02

0.38

(0.19–0.74)

0.004

0.61

(0.29–1.28)

0.19

0.94

(0.48–1.82)

0.85

Formate

1.48

(0.72–3.04)

0.29

0.57

(0.27–1.20)

0.14

0.50

(0.17–1.46)

0.21

1.06

(0.46–2.47)

0.89

Butyrate

1.87

(1.50–3.32)

0.03

0.75

(0.46–1.22)

0.25

0.71

(0.37–1.33)

0.28

0.92

(0.53–1.60)

0.76

Valerate

1.56

(1.03–2.36)

0.03

0.78

(0.54–1.12)

0.18

0.81

(0.49–1.35)

0.42

1.13

(0.72–1.77)

0.59

α-methylbutyrate

3.40

(1.22–9.5)

0.02

0.34

(0.14–0.86)

0.02

0.31

(0.10–0.93)

0.04

0.58

(0.23–1.45)

0.25

Isobutyrate

2.30

(0.97–5.44)

0.06

0.33

(0.014–0.80)

0.01

0.38

(0.14–1.02)

0.054

0.75

(0.34–1.73)

0.52

Isovalerate

0.98

(0.52–1.84)

0.96

0.59

(0.29–1.22)

0.15

0.57

(0.19–1.74)

0.33

1.06

(0.53–2.15)

0.86